Jared M Baeten1, Deborah Donnell2, Nelly R Mugo3, Patrick Ndase4, Katherine K Thomas4, James D Campbell5, Jonathan Wangisi6, Jordan W Tappero7, Elizabeth A Bukusi8, Craig R Cohen9, Elly Katabira10, Allan Ronald11, Elioda Tumwesigye12, Edwin Were13, Kenneth H Fife14, James Kiarie15, Carey Farquhar16, Grace John-Stewart17, Lara Kidoguchi4, Robert W Coombs18, Craig Hendrix19, Mark A Marzinke19, Lisa Frenkel20, Jessica E Haberer21, David Bangsberg21, Connie Celum16. 1. Department of Global Health, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA. Electronic address: jbaeten@uw.edu. 2. Department of Global Health, University of Washington, Seattle, WA, USA; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 3. Department of Global Health, University of Washington, Seattle, WA, USA; Centres for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya. 4. Department of Global Health, University of Washington, Seattle, WA, USA. 5. Centers for Disease Control and Prevention, Entebbe, Uganda. 6. AIDS Support Organization, Kampala, Uganda. 7. Centers for Disease Control and Prevention, Atlanta, GA, USA. 8. Department of Global Health, University of Washington, Seattle, WA, USA; Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya; Department of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital, Nairobi, Kenya; Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA, USA. 9. Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA, USA. 10. Infectious Disease Institute, Makerere University, Kampala, Uganda. 11. Infectious Disease Institute, Makerere University, Kampala, Uganda; Department of Medicine, University of Manitoba, Winnipeg, Canada. 12. Kabwohe Clinical Research Center, Kabwohe, Uganda. 13. Department of Reproductive Health, Moi University, Eldoret, Kenya. 14. Department of Medicine, Indiana University, Indianapolis, IN, USA. 15. Department of Global Health, University of Washington, Seattle, WA, USA; Department of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital, Nairobi, Kenya. 16. Department of Global Health, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA. 17. Department of Global Health, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA. 18. Department of Medicine, University of Washington, Seattle, WA, USA; Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. 19. Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 20. Department of Laboratory Medicine, University of Washington, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA; Seattle Children's Hospital Research Institute, Seattle, WA, USA. 21. Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND:Antiretroviral pre-exposure prophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtricitabine, has been shown to be efficacious for HIV-1 prevention. Although the use of more than one antiretroviral agent is essential for effective HIV-1 treatment, more than one agent might not be required for effective prophylaxis. We assessed the efficacy of single-agent tenofovir disoproxil fumarate relative to combination emtricitabine plus tenofovir disoproxil fumarate as PrEP. METHODS: We did a randomised, double-blind, placebo-controlled three-group phase 3 trial of daily oral tenofovir disoproxil fumarate and emtricitabine plustenofovir disoproxil fumarate PrEP in HIV-1 uninfected individuals in heterosexual HIV-1 serodiscordant couples from Kenya and Uganda. After an interim review, the trial's placebo group was discontinued and thereafter the active groups were continued, and participants initially randomly assigned to placebo were offered rerandomisation in a 1:1 ratio to tenofovir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate as PrEP. The primary endpoints were HIV-1 seroconversion and safety. This trial is registered with ClinicalTrials.gov, number NCT00557245. FINDINGS: 4410 (99·6%) of 4427 couples received tenofovir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate and were followed up for HIV-1 acquisition. Of 52 incident HIV-1 infections, 31 occurred in individuals assigned tenofovir disoproxil fumarate (incidence 0·71 cases per 100 person-years) and 21 were in those assigned emtricitabine plus tenofovir disoproxil fumarate (0·48 cases per 100 person-years); HIV-1 incidence in the placebo group until discontinuation was two cases per 100 person-years. HIV-1 prevention efficacy with emtricitabine plus tenofovir disoproxil fumarate was not significantly different from that of tenofovir disoproxil fumarate alone (hazard ratio [HR] 0·67, 95% CI 0·39-1·17; p=0·16). Detection of tenofovir in plasma samples, compared with no detection and as measured in seroconverters and a subset of non-seroconverters, was associated with an 85% relative risk reduction in HIV-1 acquisition for the tenofovir disoproxil fumarate group (HR 0·15, 95% CI 0·06-0·37; p<0·0001) and 93% for the emtricitabine plus tenofovir disoproxil fumarate group (0·07, 0·02-0·23; p<0·0001). No significant differences were noted in the frequency of deaths, serious adverse events, or serum creatinine and phosphorus abnormalities between the two groups. INTERPRETATION: These results do not rule out the potential for a slight difference in HIV-1 protection with tenofovir disoproxil fumarate compared with emtricitabine plus tenofovir disoproxil fumarate, but show that once-daily oral tenofovir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate regimens both provide high protection against HIV-1 acquisition in heterosexual men and women. FUNDING: Bill & Melinda Gates Foundation and US National Institutes of Health.
RCT Entities:
BACKGROUND: Antiretroviral pre-exposure prophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtricitabine, has been shown to be efficacious for HIV-1 prevention. Although the use of more than one antiretroviral agent is essential for effective HIV-1 treatment, more than one agent might not be required for effective prophylaxis. We assessed the efficacy of single-agent tenofovir disoproxil fumarate relative to combination emtricitabine plus tenofovir disoproxil fumarate as PrEP. METHODS: We did a randomised, double-blind, placebo-controlled three-group phase 3 trial of daily oral tenofovir disoproxil fumarate and emtricitabine plus tenofovir disoproxil fumarate PrEP in HIV-1 uninfected individuals in heterosexual HIV-1 serodiscordant couples from Kenya and Uganda. After an interim review, the trial's placebo group was discontinued and thereafter the active groups were continued, and participants initially randomly assigned to placebo were offered rerandomisation in a 1:1 ratio to tenofovir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate as PrEP. The primary endpoints were HIV-1 seroconversion and safety. This trial is registered with ClinicalTrials.gov, number NCT00557245. FINDINGS: 4410 (99·6%) of 4427 couples received tenofovir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate and were followed up for HIV-1 acquisition. Of 52 incident HIV-1 infections, 31 occurred in individuals assigned tenofovir disoproxil fumarate (incidence 0·71 cases per 100 person-years) and 21 were in those assigned emtricitabine plus tenofovir disoproxil fumarate (0·48 cases per 100 person-years); HIV-1 incidence in the placebo group until discontinuation was two cases per 100 person-years. HIV-1 prevention efficacy with emtricitabine plus tenofovir disoproxil fumarate was not significantly different from that of tenofovir disoproxil fumarate alone (hazard ratio [HR] 0·67, 95% CI 0·39-1·17; p=0·16). Detection of tenofovir in plasma samples, compared with no detection and as measured in seroconverters and a subset of non-seroconverters, was associated with an 85% relative risk reduction in HIV-1 acquisition for the tenofovir disoproxil fumarate group (HR 0·15, 95% CI 0·06-0·37; p<0·0001) and 93% for the emtricitabine plus tenofovir disoproxil fumarate group (0·07, 0·02-0·23; p<0·0001). No significant differences were noted in the frequency of deaths, serious adverse events, or serum creatinine and phosphorus abnormalities between the two groups. INTERPRETATION: These results do not rule out the potential for a slight difference in HIV-1 protection with tenofovir disoproxil fumarate compared with emtricitabine plus tenofovir disoproxil fumarate, but show that once-daily oral tenofovir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate regimens both provide high protection against HIV-1 acquisition in heterosexual men and women. FUNDING: Bill & Melinda Gates Foundation and US National Institutes of Health.
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: J Gerardo García-Lerma; Mian-er Cong; James Mitchell; Ae S Youngpairoj; Qi Zheng; Silvina Masciotra; Amy Martin; Zsuzsanna Kuklenyik; Angela Holder; Jonathan Lipscomb; Chou-Pong Pau; John R Barr; Debra L Hanson; Ron Otten; Lynn Paxton; Thomas M Folks; Walid Heneine Journal: Sci Transl Med Date: 2010-01-13 Impact factor: 17.956
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Ingrid A Beck; Claudia Crowell; Robin Kittoe; Helba Bredell; Molefe Machaba; Carolyn Willamson; Wouter Janssens; Sabelle Jallow; Guido van der Groen; Yiming Shao; Mini Jacob; N M Samuel; Ivette Lorenzana de Rivera; Nicole Ngo-Giang-Huong; Sharon Cassol; George Alemnji; Lisa M Frenkel Journal: J Acquir Immune Defic Syndr Date: 2008-08-01 Impact factor: 3.731
Authors: Holly Janes; Lawrence Corey; Gita Ramjee; Lindsay N Carpp; Carl Lombard; Myron S Cohen; Peter B Gilbert; Glenda E Gray Journal: AIDS Res Hum Retroviruses Date: 2018-06-19 Impact factor: 2.205
Authors: Charlene S Dezzutti; Laura J Else; Sarah E Yandura; Cory Shetler; Julie Russo; David J Back; Ian McGowan Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191
Authors: Andrew Mujugira; Robert W Coombs; Renee Heffron; Connie Celum; Allan Ronald; Nelly Mugo; Jared M Baeten Journal: J Infect Dis Date: 2016-04-06 Impact factor: 5.226
Authors: Kenneth K Mugwanya; Jared M Baeten; Christina Wyatt; Nelly R Mugo; Connie L Celum; Allan Ronald; John Kiarie; Elly Katabira; Renee Heffron Journal: J Acquir Immune Defic Syndr Date: 2018-02-01 Impact factor: 3.731
Authors: Dara A Lehman; Jared M Baeten; Connor O McCoy; Julie F Weis; Dylan Peterson; Gerald Mbara; Deborah Donnell; Katherine K Thomas; Craig W Hendrix; Mark A Marzinke; Lisa Frenkel; Patrick Ndase; Nelly R Mugo; Connie Celum; Julie Overbaugh; Frederick A Matsen Journal: J Infect Dis Date: 2015-01-13 Impact factor: 5.226
Authors: Sharon M Seifert; Xinhui Chen; Amie L Meditz; Jose R Castillo-Mancilla; Edward M Gardner; Julie A Predhomme; Carolyn Clayton; Gregory Austin; Brent E Palmer; Jia-Hua Zheng; Brandon Klein; Becky J Kerr; L Anthony Guida; Caitlin Rower; Joseph E Rower; Jennifer J Kiser; Lane R Bushman; Samantha MaWhinney; Peter L Anderson Journal: AIDS Res Hum Retroviruses Date: 2016-09-19 Impact factor: 2.205
Authors: Jennifer LeMessurier; Gregory Traversy; Olivia Varsaneux; Makenzie Weekes; Marc T Avey; Oscar Niragira; Robert Gervais; Gordon Guyatt; Rachel Rodin Journal: CMAJ Date: 2018-11-19 Impact factor: 8.262